When a child or young person with B-cell non-Hodgkin lymphoma relapses after standard chemotherapy, the outlook becomes one of the most daunting challenges in paediatric oncology. These cancers, which arise from mature B lymphocytes and include diffuse large B-cell lymphoma and Burkitt lymphoma among others, are often curable at first diagnosis, but once they return or resist treatment, options narrow sharply and survival rates fall dramatically. Now an unprecedented international effort is being launched to change that picture. Known as Glo-BNHL, the trial is a multi-arm, adaptive platform study designed to test several classes of novel targeted agents simultaneously in children, adolescents and young adults up to 25 years of age whose disease has relapsed or proved refractory to conventional therapy.
The trial’s origins lie in a deliberate, consensus-driven prioritisation exercise. At the second Paediatric Strategy Forum of ACCELERATE, an international multi-stakeholder organisation that brings together clinicians, regulators, industry, patients and families, experts concluded in November 2017 that no single country could mount meaningful trials in this rare disease setting alone. They agreed that an international approach was critical, and that robust prioritisation of novel targeted agents was essential so that only those showing maximum potential would advance into clinical investigation. That conclusion has now crystallised into a fully designed protocol, published in BMC Cancer, with trial registration on ClinicalTrials.gov under identifier NCT05991388 since July 2023.
Glo-BNHL is structured as a platform trial, a design philosophy borrowed from other areas of medicine where speed and flexibility matter most. Rather than testing one drug against another in a fixed comparison, a platform trial provides a permanent clinical infrastructure into which multiple treatment arms can be slotted. In this case, the ACCELERATE Forum identified three classes of agents for immediate prioritisation: bispecific antibodies, antibody-drug conjugates combined with standard chemotherapy, and chimeric antigen receptor T-cells, better known as CAR T-cells. Each class represents a distinct strategy for attacking malignant B-cells, and promising agents from each will be evaluated in parallel treatment arms running concurrently within the same study.
The technical sophistication of the trial lies in its adaptive Bayesian statistical design. Bayesian methods allow researchers to update the probability that a treatment is working as data accumulate, rather than waiting until a pre-fixed sample size has been exhausted. This is crucial in a rare paediatric cancer, where the number of eligible patients at any given time is small and every participant counts. The design facilitates efficient GO or NO-GO decisions even with small numbers of participants registered into each arm. Each treatment arm begins with an initial stage evaluating efficacy, and if the signals are promising, an expansion stage can follow to provide confirmatory analysis. Equally important, if the scientific landscape shifts and prioritisation of drug classes changes, the adaptive architecture allows treatment arms to be added or removed to reflect the new evidence, keeping the platform current without the delay of launching an entirely new trial.
The first two agents to enter the platform illustrate the diversity of the approaches being tested. Treatment Arm I will evaluate odronextamab, a bispecific antibody supplied by Regeneron, which is also providing funding to support a fit-for-filing trial for that arm. Bispecific antibodies are engineered proteins capable of binding two targets at once, in this case simultaneously tethering a malignant B-cell to a cytotoxic T-cell so the immune cell can destroy the cancer. The primary outcome for this arm is the occurrence of an objective response after 12 weeks of treatment. Treatment Arm II will evaluate loncastuximab tesirine, an antibody-drug conjugate supplied by ADC Therapeutics, combined with a modified R-ICE chemotherapy regimen. Antibody-drug conjugates work as targeted delivery vehicles, using an antibody to ferry a potent cytotoxic payload directly to CD19-expressing tumour cells while limiting collateral damage to healthy tissue. For this arm, the primary outcome is the occurrence of a complete response within a maximum of three treatment cycles.
The third prioritised class, CAR T-cells, involves a fundamentally different therapeutic logic. Instead of administering a drug, clinicians collect a patient’s own T lymphocytes, engineer them in the laboratory to express a chimeric antigen receptor that recognises a marker on the surface of malignant B-cells, expand the modified cells, and infuse them back into the patient. The trial’s primary outcome for this arm is the occurrence of an objective response following CAR T-cell infusion. Because these living drugs can trigger distinctive immune-mediated toxicities, the protocol pays close attention to adverse events of special interest, including cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, both of which are graded according to standards established by the American Society for Transplantation and Cellular Therapy.
Eligibility for the trial is carefully defined to capture the right patient population at the right moment. Participants must be 25 years old or younger, with histologically proven mature B-cell non-Hodgkin lymphoma at initial diagnosis and radiologically or histologically proven disease at first or subsequent relapse, or refractory disease that failed to respond to frontline therapy. Patients must have a Karnofsky or Lansky performance status of at least 50, a measure of functional wellbeing that ensures participants are well enough to tolerate investigational treatment. Written informed consent is required from participants or, for children, from parents or legal guardians, and the protocol received initial ethical approval in the United Kingdom from the London City and East Research Ethics Committee in October 2023.
The scale of international coordination behind Glo-BNHL is itself a technical achievement. The trial is led from the United Kingdom, anchored at the Cancer Research UK Clinical Trials Unit at the University of Birmingham, with national coordinating centres in Australasia, Europe and North America. Collaborating organisations include the European Inter-Group for Childhood Non-Hodgkin Lymphoma, the Children’s Oncology Group and the Innovative Therapies for Children and Adolescents with Cancer, alongside investigators from leading paediatric cancer centres across the United States, Canada, France, the Netherlands, Germany and beyond. The study is investigator-initiated and investigator-led, with core funding from Fight Kids Cancer and Cancer Research UK, and pharmaceutical partners supplying the investigational agents and supporting the fit-for-filing components of the first two arms.
Notably, the trial has embedded patient and public involvement from its inception. Representatives of patients and families, including contributors from parent-led foundations and the Coalition Against Childhood Cancer, have helped shape the study and its conduct, a reflection of a broader movement in paediatric oncology to ensure that research priorities align with what matters most to the young people affected. Trial governance includes a trial steering committee, a trial management group and an independent data monitoring committee, the standard safeguards that protect participant safety and study integrity as results accumulate across multiple arms and countries.
The significance of Glo-BNHL extends beyond any single drug. In this rare cancer setting, the platform presents a unique opportunity to evaluate multiple promising novel agents within the same trial, avoiding the years of delay and duplicated infrastructure that separate conventional one-drug, one-trial studies. Its designers state explicitly that the study is intended to generate sufficient evidence to be practice-changing, meaning that positive results could directly reshape how relapsed and refractory B-cell lymphoma is treated in young patients worldwide. For families confronting a relapse diagnosis, where time is the scarcest resource, the promise of a system that can rapidly identify which immunotherapies and targeted agents truly work represents a meaningful shift in how evidence for rare childhood cancers is built. As the first participants are enrolled and the Bayesian machinery begins to weigh each new data point, Glo-BNHL stands as a test case for whether global, adaptive, multi-stakeholder trial design can deliver answers faster for the children who need them most.
Subject of Research: Adaptive international platform trial testing novel targeted agents in paediatric relapsed and refractory B-cell non-Hodgkin lymphoma
Article Title: A global study of novel agents in paediatric and adolescent relapsed and refractory B-cell non-Hodgkin lymphoma (Glo-BNHL): protocol for an adaptive international platform clinical trial
Article References: Burke, G. A. A., Seaford, E., Lax, S., Lawson, A., Williams, E., Rogers, J., Johnson, S., Deshpande, A., Ahmed, Z., Muzaffar, M., Maycock, S., Wang, J., Bollard, C. M., Allen, C. E., Auperin, A., Gore, L., Kearns, P., Beishuizen, A., Minard-Colin, V., … Billingham, L. (2026). A global study of novel agents in paediatric and adolescent relapsed and refractory B-cell non-Hodgkin lymphoma (Glo-BNHL): protocol for an adaptive international platform clinical trial. BMC Cancer. https://doi.org/10.1186/s12885-026-16969-1
Image Credits: AI Generated
DOI: 10.1186/s12885-026-16969-1
Keywords: B-cell non-Hodgkin lymphoma, platform trial, adaptive Bayesian design, bispecific antibodies, antibody-drug conjugates, CAR T-cells, paediatric oncology, relapsed refractory cancer, odronextamab, loncastuximab tesirine, ACCELERATE, clinical trial protocol
Cite Scienmag News
APA MLA Chicago
Nathaniel Bowman. (October 3, 2026). Global Platform Trial Aims to Transform Treatment of Children With Relapsed B-Cell Lymphoma. Scienmag. https://scienmag.com/global-platform-trial-aims-to-transform-treatment-of-children-with-relapsed-b-cell-lymphoma/
Nathaniel Bowman. “Global Platform Trial Aims to Transform Treatment of Children With Relapsed B-Cell Lymphoma.” Scienmag, 3 October 2026, https://scienmag.com/global-platform-trial-aims-to-transform-treatment-of-children-with-relapsed-b-cell-lymphoma/. Accessed 3 October 2026.
Nathaniel Bowman. “Global Platform Trial Aims to Transform Treatment of Children With Relapsed B-Cell Lymphoma.” Scienmag. October 3, 2026. https://scienmag.com/global-platform-trial-aims-to-transform-treatment-of-children-with-relapsed-b-cell-lymphoma/
Copy citation Download RIS
Tags: ACCELERATEACCELERATE Paediatric Strategy Forum initiativesadaptive Bayesian designadvancements in targeted agents for refractory lymphomaantibody-drug conjugatesB-cell non-Hodgkin lymphomabispecific antibodiesCAR T cellsclinical trial protocolcollaborative efforts in pediatric cancer researchGlobal platform trial for relapsed pediatric B-cell lymphomaimproving survival rates in relapsed childhood lymphomainternational adaptive clinical trial for childhood lymphomainternational cooperation in rare pediatric cancersloncastuximab tesirinemulti-arm platform study in pediatric oncologymulti-stakeholder approach to pediatric cancer trialsnovel targeted therapies for relapsed B-cell non-Hodgkin lymphomaodronextamabpaediatric oncologyplatform trialrelapsed refractory cancertreatment strategies for relapsed childhood lymphoma
